

For media and investors only
19th June 2025

XIV International Congress of Dermatology (ICD)

Almirall shows efficacy of biologics with real-world evidence and new patient-centric research on psychological wellbeing at the 2025 International Congress of Dermatology

- **Almirall's scientific symposia at ICD will focus on new real world clinical data on lebrikizumab's efficacy and safety in atopic dermatitis and address clinical opportunities in managing difficult-to-treat psoriasis with tildrakizumab**
- **Research shows lebrikizumab effectively treats moderate-to-severe atopic dermatitis, improving both skin signs and symptoms and the overall patient's psychological wellbeing over time**
- **Almirall also presents interim results of the POSITIVE study with data on key symptoms and psychological wellbeing in psoriasis patients treated with tildrakizumab**
- **In parallel to the congress, the PsOlive Challenge, a global call for innovative projects promoting a holistic approach to long-term psoriasis care, will culminate on June 20th, with the finalist projects getting a chance to pitch their proposals in front of an independent jury, who will adjudicate a grant to the selected project**

Rome, Italy. June 19th, 2025 – Almirall, a global pharmaceutical company dedicated to medical dermatology, will be a key contributor at **the upcoming International Congress of Dermatology (ICD)**, taking place from June 18 to 21, 2025, in Rome, Italy. Almirall participates with two scientific symposia, a series of poster presentations, and a commercial exhibition stand.

Held every four years, the **ICD** brings together researchers, leading dermatologists, and other healthcare professionals from across the globe to exchange knowledge, clinical practices, and innovations in dermatology.

Scientific Contributions at ICD

Almirall's scientific contributions at the congress focus on recent findings in both atopic dermatitis and psoriasis. The company presents several posters based on lebrikizumab's ADvocate 1 and 2 monotherapy trials, which were designed to demonstrate its efficacy over time in both skin signs and symptoms in patients with moderate-to-severe atopic dermatitis, measured by absolute scores which are more relevant in clinical practice¹.

The data from the ADvantage clinical trial show that lebrikizumab in combination with topical corticosteroids significantly improved signs and symptoms of AD in adults and adolescents with moderate-to-severe AD up at Week 16 and Week 52²³.

Almirall also presents **interim results from the POSITIVE study in psoriasis patients**: the first clinical study in dermatology to evaluate patients' psychological wellbeing as a primary endpoint using the WHO-5 Well-being Index. The posters show the improvement of key symptoms and psychological wellbeing in patients treated with tildrakizumab, as well as the relationship between different symptom patterns in individuals with moderate-to-severe plaque psoriasis^{4,5}.

Almirall's recent work on actinic keratosis (AK) highlights new data related to the TIRBASKIN study and tirbanibulin effect in SKINDEX-16 questionnaire improving patients' quality of life across 3 dimensions (symptoms, emotions and functioning). The well-balanced efficacy and safety/tolerability profile of tirbanibulin led to an 83% mean AK lesion count reduction from baseline to day 57⁶⁷. This shows consistent results between pivotal trials and in clinical practice, consolidating tirbanibulin as a valuable choice among AK treatments⁸.

Symposia

The first of Almirall's two expert-led scientific symposia, titled ***"Integrating Patient Voices and Treatment Advances in AD"***, will be taking place on **19 June 2025 at 12:30 and** chaired by Professor Luca Stingeni (Italy). The symposium will feature Dr. Ignasi Figueras Nart (Spain) who will give an overview of atopic dermatitis, linking the pathophysiological basis of the disease to a more patient-focused clinical approach. Dr. Andreas Pinter (Germany) will share insights into the efficacy and safety profile of lebrikizumab, highlighting recent results from clinical trials. Dr. Silvia Ferrucci (Italy) will examine the real-world impact of this treatment, bridging between research and everyday clinical practice.

"The International Congress of Dermatology (ICD) offers a fantastic opportunity to share clinical experiences, both diagnostic and therapeutic, especially concerning inflammatory skin diseases. During the Almirall symposium, we will discuss the real-life Italian experience with a new monoclonal antibody targeting IL-13 for moderate to severe atopic dermatitis. The real-life results are consistent with, or even surpass, those observed in registration studies, both in terms of disease signs and patient-reported outcomes", said **Dr Silvia Ferruci**, IRCCS Ca' Granda Foundation - Maggiore Policlinico Hospital in Milan.

The second symposium, titled ***"Are the difficult-to-treat patients with psoriasis still difficult to treat?"***, will be held on **20 June 2025 at 13:30** and will address the management of difficult to treat psoriasis areas. Chaired by Prof. Francesca Prignano (Italy), the session will feature Dr. Nina Magnolo (Germany), who will focus on the impact of difficult-to-treat areas on patients' quality of life, and Prof. Anna Campanati (Italy), who will present results on tildrakizumab from the first Phase 3b clinical trial assessing the efficacy of an IL-23 inhibitor specifically for scalp psoriasis—an area that is often difficult to treat.

According to **Dr. Nina Magnolo**, head of Central study coordination for innovative Dermatology (ZiD), Department of Dermatology at University Hospital of Muenster (UKM) *"patients with psoriasis experience worse burden of disease when difficult-to-treat areas are affected. It is essential that we continue to elevate awareness and tailor our treatment strategies to address specific challenges. By focusing on hard-to-treat areas and presenting new clinical evidence, we aim to empower clinicians with insights that can meaningfully improve patient outcomes."*

“Our participation in the International Congress of Dermatology reflects Almirall’s continuous focus on advancing science and innovation in medical dermatology. Our close collaborations and partnerships with dermatologists and healthcare professionals around the world are a cornerstone for our dedication to delivering meaningful solutions that improve patients’ lives. The ICD offers an important opportunity to collectively push the boundaries of science and advance the standards of care in dermatology,” said **Dr. Volker Koscielny, Almirall’s Chief Medical Officer.**

Almirall will announce the selected project from the **PsOlive Challenge**, a call for innovative projects, holistic approaches to long-term psoriasis care in parallel to the ICD conference. After receiving more than 25 proposals from academic and healthcare institutions across Italy, France, Germany, and Spain, five finalist teams were eligible to enter a coaching phase, where they refined their ideas based on expert coaching. An Independent Jury will announce the team selected for the PsOlive grant.

As part of Almirall’s commitment to addressing patient needs, the conference exhibition stand at the ICD features the company’s initiative called “Sanctuary Salon” which aims to educate about the impact of skin conditions like psoriasis, atopic dermatitis, and actinic keratosis on daily life and self-care, especially in the scalp area which involves 80% of psoriasis patients^{9,10} and often creates challenges for patients visiting hair dressers.¹¹

About Almirall

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: *to transform the patients’ world by helping them realize their hopes and dreams for a healthy life.* We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients’ needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

For more information, please visit <https://www.almirall.com/>

Corporate Communications:
corporate.communication@almirall.com
Phone: +34 93 291 35 08

Investor Relations
investors@almirall.com
Phone: (+34) 93 291 30 87

Legal notice:

This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are “forward-looking statements.” These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.

¹ Diamant Taçi et al. Absolute EASI response achieved with lebrikizumab over 16 and 52 weeks in patients with moderate-to-severe atopic dermatitis. Presented at the 14th International congress of dermatology. 19-21. June 2025. Rome. P528

² Jacek C Szepietowski et al. Impact of lebrikizumab in combination with topical corticosteroids in the psychological wellbeing of patients with moderate-to-severe atopic dermatitis: a randomized phase 3 clinical study (Advantage). Presented at the 14th International congress of dermatology. 19-21. June 2025. Rome. P500

³ Richard B Warren et al. Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients inadequately controlled or ineligible for cyclosporine: week 16 and Week 52 results of a phase 3 clinical study (Advantage). Presented at the 14th International congress of dermatology. 19-21. June 2025. Rome. P543

⁴ Augustin M, et al. Improvement of High Burdensome Symptoms and Psychological Well-being in Patients with Moderate-to-Severe Plaque Psoriasis Using Tildrakizumab. Presented at the 14th International congress of dermatology. 19-21. June 2025. Rome. P1324

⁵ Ulrich Mrowietz et al. Relationship between Different High Burdensome Symptoms in Patients with Moderate-to-Severe Plaque Psoriasis Using Tildrakizumab. Presented at the 14th International congress of dermatology. 19-21. June 2025. Rome. P1304

⁶ Schkesinger T et al. J of Skin. 2023 ;7(3) :771-787.

⁷ Blauvelt A, Kempers S, Lain E, et al. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. *N Engl J Med.* 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040.

⁸ Gilberte et al. Tirbanibulin 1% ointment for actinic keratosis in in Spain and Italy: quality of life, efficacy and safety results from the TIRBASKIN study. 2025 International Congress of Dermatology. 19 June 2025. Presented at the 14th International congress of dermatology. 19-21. June 2025. Rome. P 753

⁹ Prignano F., Brunasso AMG, Fabrocini G, Argenciano G. et al. Sharing Patient and Clinican Experiences of Moderate-to-Serve Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. *J Clin Med.* 2022 May 16;11(10):2801. doi: 10.3390/jcm11102801. PMID: 35628929; PMCID: PMC9146704.

¹⁰ Hillhorst N, Deprez E, Pauwels N, Grine L. et al. Patient-Relevant Outcomes in Psoriasis: A Systematic Review. *JAMA Dermatol.* 2022 Jul 1;158(7):806-811. doi 10-1001/jamadermatol.20221756. PMID: 35675070

¹¹ Prignano F, Brunasso AMG, Fabrocini G, Argenciano G. et al. Sharing Patient and Clinican Experiences of Moderate-to-Serve Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. *J Clin Med.* 2022 May 16;11(10):2801. doi: 10.3390/jcm11102801. PMID: 35628929; PMCID: PMC9146704.